National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- Adverse Drug Events (ADE) (1)
- Asthma (1)
- (-) Behavioral Health (13)
- Children/Adolescents (3)
- Comparative Effectiveness (2)
- Dementia (1)
- Depression (3)
- Emergency Department (2)
- Evidence-Based Practice (1)
- Healthcare Costs (2)
- Healthcare Utilization (1)
- Hospitalization (2)
- Medicaid (2)
- Medicare (2)
- (-) Medication (13)
- Medication: Safety (1)
- Patient-Centered Outcomes Research (1)
- Patient Adherence/Compliance (2)
- Practice Patterns (1)
- Pregnancy (1)
- Prevention (1)
- Risk (1)
- Tobacco Use (1)
- U.S. Preventive Services Task Force (USPSTF) (1)
- Women (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 13 of 13 Research Studies DisplayedAmick HR, Gartlehner G, Gaynes BN
Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis.
This systematic review sought to identify the benefits and harms of second generation antidepressants and cognitive behavioral therapies (CBTs) in the initial treatment of a current episode of major depressive disorder in adults. It concluded that the available evidence suggests no difference in treatment effects of second generation antidepressants and CBT, either alone or in combination, although small numbers may preclude detection of small but clinically meaningful differences.
AHRQ-funded; 290-2012-00008I
Citation: Amick HR, Gartlehner G, Gaynes BN .
Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis.
BMJ 2015 Dec 8;351:h6019. doi: 10.1136/bmj.h6019..
Keywords: Medication, Behavioral Health, Comparative Effectiveness, Depression
Patnode CD, Henderson JT, Thompson JH
Behavioral counseling and pharmacotherapy interventions for tobacco cessation in adults, including pregnant women: a review of reviews for the U.S. Preventive Services Task Force.
The researchers reviewed the effectiveness and safety of pharmacotherapy and behavioral interventions for tobacco cessation. They concluded that behavioral and pharmacotherapy interventions improve rates of smoking cessation among the general adult population, alone or in combination. Data on the effectiveness and safety of electronic nicotine delivery systems are limited.
AHRQ-funded; 290201200015I.
Citation: Patnode CD, Henderson JT, Thompson JH .
Behavioral counseling and pharmacotherapy interventions for tobacco cessation in adults, including pregnant women: a review of reviews for the U.S. Preventive Services Task Force.
Ann Intern Med 2015 Oct 20;163(8):608-21. doi: 10.7326/m15-0171..
Keywords: Behavioral Health, Evidence-Based Practice, Medication, Pregnancy, Prevention, Tobacco Use, U.S. Preventive Services Task Force (USPSTF), Women
Gerhard T, Devanand DP, Huang C
Lithium treatment and risk for dementia in adults with bipolar disorder: population-based cohort study.
This study examined the association of lithium and dementia risk in a large claims-based US cohort of publicly insured older adults with bipolar disorder. It found that compared with non-use, 301–365 days of lithium exposure was associated with significantly reduced dementia risk. No corresponding association was observed for shorter lithium exposures.
AHRQ-funded; HS021112.
Citation: Gerhard T, Devanand DP, Huang C .
Lithium treatment and risk for dementia in adults with bipolar disorder: population-based cohort study.
Br J Psychiatry 2015 Jul;207(1):46-51. doi: 10.1192/bjp.bp.114.154047..
Keywords: Dementia, Risk, Behavioral Health, Medication
Lu CY, Zhang F, Lakoma MD
Asthma treatments and mental health visits after a Food and Drug Administration label change for leukotriene inhibitors.
This study investigated how a label change to include neuropsychiatric adverse events (e.g., depression and suicidality) affected the use of leukotriene inhibitors (LTIs) and other asthma controller medications, mental health visits, and suicide attempts. The label change was associated with abrupt reductions in LTI use among all age groups.
AHRQ-funded; HS019669.
Citation: Lu CY, Zhang F, Lakoma MD .
Asthma treatments and mental health visits after a Food and Drug Administration label change for leukotriene inhibitors.
Clin Ther 2015 Jun;37(6):1280-91. doi: 10.1016/j.clinthera.2015.03.027..
Keywords: Adverse Drug Events (ADE), Asthma, Children/Adolescents, Medication, Behavioral Health
Samples H, Mojtabai R
Antidepressant self-discontinuation: results from the collaborative psychiatric epidemiology surveys.
The authors examined the extent and correlates of self-discontinuation of antidepressant medications without physician advice using the Collaborative Psychiatric Epidemiology Surveys. They concluded that physicians prescribing antidepressants need to communicate clearly about the expected benefits of treatment, the minimum duration of use required to experience benefits, and the potential side effects of these medications, particularly to younger patients, those with anxiety disorders, and patients treated in general medical settings, all of whom have increased odds of self-discontinuation.
AHRQ-funded; HS000029.
Citation: Samples H, Mojtabai R .
Antidepressant self-discontinuation: results from the collaborative psychiatric epidemiology surveys.
Psychiatr Serv 2015 May;66(5):455-62. doi: 10.1176/appi.ps.201400021.
.
.
Keywords: Medication, Depression, Medication: Safety, Behavioral Health, Patient Adherence/Compliance
Predmore ZS, Mattke S, Horvitz-Lennon M
Improving antipsychotic adherence among patients with schizophrenia: savings for states.
The authors presented findings of an analysis conducted to quantify the potential net savings to state budgets from interventions to improve adherence to antipsychotic drugs among patients with schizophrenia. Their financial model estimated an annual cost of $21.4 billion (in 2013 dollars) to Medicaid programs and other state agencies for people with schizophrenia. They concluded that better adherence could yield annual net savings of $3.28 billion to states and recommended that states consider interventions shown to increase medication adherence in this patient group.
AHRQ-funded; HS000029.
Citation: Predmore ZS, Mattke S, Horvitz-Lennon M .
Improving antipsychotic adherence among patients with schizophrenia: savings for states.
Psychiatr Serv 2015 Apr;66(4):343-5. doi: 10.1176/appi.ps.201400506.
.
.
Keywords: Healthcare Costs, Medication, Behavioral Health, Patient Adherence/Compliance
Olfson M
Surveillance of adverse psychiatric medication events.
This article estimates the numbers and rates of adverse drug event (ADE) emergency department (ED) visits involving psychiatric medications among US adults between January 1, 2009, and December 31, 2011. The author finds that there were an estimated 89,094 psychiatric medication ADE emergency department visits annually, with 19.3 percent resulting in hospitalization and 49.4 percent involving patients aged 19 to 44.
AHRQ-funded; HS021112.
Citation: Olfson M .
Surveillance of adverse psychiatric medication events.
JAMA 2015 Mar 24-31;313(12):1256-7. doi: 10.1001/jama.2014.15743..
Keywords: Emergency Department, Behavioral Health, Hospitalization, Medication
Morrato EH, Parks J, Campagna EJ
Comparative effectiveness of injectable paliperidone palmitate versus oral atypical antipsychotics: early postmarketing evidence.
The researchers compared the likelihood of hospitalization and emergency department visits in Medicaid patients from the state of Missouri starting paliperidone palmitate versus oral atypical (also known as second-generation) antipsychotics. They found that paliperidone palmitate treatment resulted in a statistically significant 37 percent reduction in the adjusted likelihood of an all-cause emergency department visit. There was no statistically significant reduction in hospitalization.
AHRQ-funded; HS019464.
Citation: Morrato EH, Parks J, Campagna EJ .
Comparative effectiveness of injectable paliperidone palmitate versus oral atypical antipsychotics: early postmarketing evidence.
J Comp Eff Res 2015 Mar-Apr;4(2):89-99. doi: 10.2217/cer.14.50..
Keywords: Medication, Hospitalization, Behavioral Health, Emergency Department, Healthcare Utilization
Garfield LD, Brown DS, Allaire BT
Psychotropic drug use among preschool children in the Medicaid program from 36 states.
The researchers examined utilization of the most commonly used psychotropic medications among children aged 4 years and younger. They determined the prevalence of and indications for psychotropic medication among preschool children in Medicaid. Their study found that preschoolers are receiving psychotropic medications despite limited evidence supporting safety or efficacy. Medications for attention-deficit disorder/attention-deficit hyperactivity disorder treatment were most common.
AHRQ-funded; HS020269.
Citation: Garfield LD, Brown DS, Allaire BT .
Psychotropic drug use among preschool children in the Medicaid program from 36 states.
Am J Public Health 2015 Mar;105(3):524-9. doi: 10.2105/ajph.2014.302258..
Keywords: Children/Adolescents, Medication, Medicaid, Behavioral Health
Zhang Y, Baik SH, Newhouse JP
Use of intelligent assignment to Medicare Part D plans for people with schizophrenia could produce substantial savings.
The investigators simulated Medicare Part D savings from replacing random assignment with an "intelligent assignment" algorithm that would assign beneficiaries to the least expensive plan in 2010 based on their drug usage in the previous year. They found that intelligent assignment could have saved about $150 million for Medicare and beneficiaries with schizophrenia combined in 2010.
AHRQ-funded; HS018657.
Citation: Zhang Y, Baik SH, Newhouse JP .
Use of intelligent assignment to Medicare Part D plans for people with schizophrenia could produce substantial savings.
Health Aff 2015 Mar;34(3):455-60. doi: 10.1377/hlthaff.2014.1227.
.
.
Keywords: Healthcare Costs, Medicare, Medication, Behavioral Health
Madden JM, Adams AS, LeCates RF
Changes in drug coverage generosity and untreated serious mental illness: transitioning from Medicaid to Medicare Part D.
This study examined the effects of transitioning to Part D coverage among disabled dual enrollees with schizophrenia or a bipolar disorder, comparing enrollees in states with strict Medicaid cap policies with enrollees in states without caps. It found significant reductions in the number of people with a serious mental illness who were not treated owing to the transition to Part D from strictly capped Medicaid coverage.
AHRQ-funded; HS018577.
Citation: Madden JM, Adams AS, LeCates RF .
Changes in drug coverage generosity and untreated serious mental illness: transitioning from Medicaid to Medicare Part D.
JAMA Psychiatry 2015 Feb;72(2):179-88. doi: 10.1001/jamapsychiatry.2014.1259..
Keywords: Behavioral Health, Medication, Medicare, Medicaid, Depression
Bobo WV, Reilly-Harrington NA, Ketter TA
Complexity of illness and adjunctive benzodiazepine use in outpatients with bipolar I or II disorder: results from the Bipolar CHOICE study.
This study examined patient- and illness-related factors associated with benzodiazepine use among patients with bipolar I or II disorder enrolled in the Bipolar CHOICE study. It found that higher anxiety symptom level, higher number of non–benzodiazepine psychotropic medications, lamotrigine use, college education, and high household income were significant and independent predictors of benzodiazepine use.
AHRQ-funded; HS019371.
Citation: Bobo WV, Reilly-Harrington NA, Ketter TA .
Complexity of illness and adjunctive benzodiazepine use in outpatients with bipolar I or II disorder: results from the Bipolar CHOICE study.
J Clin Psychopharmacol 2015 Feb;35(1):68-74. doi: 10.1097/jcp.0000000000000257..
Keywords: Medication, Behavioral Health, Practice Patterns
Christian RB, Gaynes BN, Saavedra LM
Use of antipsychotic medications in pediatric and young adult populations: future research needs.
This article describes and prioritizes future research needs regarding antipsychotic treatment in youth, focusing on within-class and between-class drug comparisons with regard to key population subgroups, efficacy and effectiveness outcomes, and adverse event outcomes. Future research needs are delineated in detail as well as study designs that could be used to address them.
AHRQ-funded; 290200710056I.
Citation: Christian RB, Gaynes BN, Saavedra LM .
Use of antipsychotic medications in pediatric and young adult populations: future research needs.
J Psychiatr Pract 2015 Jan;21(1):26-36. doi: 10.1097/01.pra.0000460619.10429.4c..
Keywords: Medication, Children/Adolescents, Behavioral Health, Comparative Effectiveness, Patient-Centered Outcomes Research